{
    "clinical_study": {
        "@rank": "121230", 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of intermittent intravenous (IV) foscarnet in the\n      treatment of acyclovir-resistant herpes simplex virus (HSV) infections in AIDS patients and\n      other immunocompromised patients. To evaluate the necessity, efficacy, and safety of IV\n      maintenance foscarnet therapy in preventing recurrent disease. To confirm the\n      pharmacokinetics of intermittent induction and maintenance IV regimens."
        }, 
        "brief_title": "An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies", 
        "condition": [
            "Herpes Simplex", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Herpes Simplex", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Cyclosporine.\n\n        Patients must have AIDS as defined by the CDC, or be patients with other immunocompromised\n        states (transplant patients; other hematologic malignancies with recognized cell-mediated\n        immune deficiency), and have herpes simplex virus (HSV) infection documented by culture\n        and in vitro resistance to acyclovir by standard laboratory susceptibility or suspected\n        resistance to acyclovir after an acyclovir treatment failure in which acyclovir was\n        administered for at least 2 weeks intravenously at doses of 30 mg/kg/day (or a comparative\n        dose adjusted for renal insufficiency).  In vitro susceptibility data must be pending in\n        the latter case.\n\n          -  Patients must be able to give informed consent.\n\n          -  Patients < 18 years of age may participate with the consent of parent, guardian, or\n             person with power of attorney, or through the provisions of state laws regarding\n             emancipated minors.\n\n          -  Expected survival of at least 6 months.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Cyclosporine.\n\n          -  Ganciclovir.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Known allergy to foscarnet.\n\n          -  Any clinically significant pulmonary or neurologic impairment (e.g., patients who are\n             intubated or comatose).\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Any potentially nephrotoxic agent (except cyclosporine).\n\n          -  Immunomodulators.\n\n          -  Biologic response modifiers.\n\n          -  Investigational agents.\n\n        Patients with the following are excluded:\n\n          -  Known allergy to foscarnet.\n\n          -  Any clinically significant pulmonary or neurologic impairment (e.g., patients who are\n             intubated or comatose).\n\n        Prior Medication:\n\n        Excluded within 7 days of entry:\n\n          -  Any potentially nephrotoxic agent (except cyclosporine).\n\n          -  Excluded within 14 days of entry:\n\n          -  Immunomodulators.\n\n          -  Biologic response modifiers.\n\n          -  Investigational agents."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002272", 
            "org_study_id": "020G", 
            "secondary_id": "89-FOS-09B"
        }, 
        "intervention": {
            "intervention_name": "Foscarnet sodium", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Acyclovir", 
                "Foscarnet", 
                "Phosphonoacetic Acid"
            ]
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Immune Tolerance", 
            "Injections, Intravenous", 
            "Herpes Simplex", 
            "Immunity, Cellular", 
            "Drug Resistance", 
            "Foscarnet", 
            "Acyclovir", 
            "Acquired Immunodeficiency Syndrome", 
            "Antiviral Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77004"
                }, 
                "name": "Foscarnet Research Program / Park Plaza Hosp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "PMID": "8106965", 
            "citation": "Balfour HH Jr, Benson C, Braun J, Cassens B, Erice A, Friedman-Kien A, Klein T, Polsky B, Safrin S. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr. 1994 Mar;7(3):254-60. Review."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002272"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astra USA", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 1990"
    }, 
    "geocoordinates": {
        "Foscarnet Research Program / Park Plaza Hosp": "29.76 -95.369"
    }
}